Includes a first use checklist of Darzalex® SC.
Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more
DARZALEX® SC handling and administration
Handling and administration demonstration & information
DARZALEX® SC support materials
A range of materials including a practical guide, in-clinic poster and patient materials
DARZALEX® SC MOA
See how the recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology) added to DARZALEX® facilitates the subcutaneous administration of the drug
IRR: infusion-related reaction
IV: intravenous
MDT: multidisciplinary team
MM: multiple myeloma
MOA: mode of action
SC: subcutaneous
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Darzalex®, veja aqui